Patient and transplantation characteristics
| Characteristics . | n (%) . |
|---|---|
| Number of patients | 5343 |
| Number of centers | 286 |
| Age at transplantation, y | |
| Median (range) | 36 (< 1-72) |
| 0-9 | 451 (8) |
| 10-19 | 665 (12) |
| 20-29 | 906 (17) |
| 30-39 | 1207 (23) |
| 40-49 | 1212 (23) |
| 50-59 | 742 (14) |
| ≥ 60 | 160 (3) |
| Male sex | 3182 (60) |
| Disease | |
| AML | 1802 (34) |
| ALL | 1140 (21) |
| CML | 1813 (34) |
| MDS | 588 (11) |
| Disease status before transplantation* | |
| Early | 2956 (55) |
| Intermediate | 1367 (26) |
| Advanced | 1020 (19) |
| Graft source | |
| Bone marrow | 3302 (62) |
| Peripheral blood | 1914 (36) |
| Umbilical cord blood | 127 (2) |
| HLA-matching status† | |
| HLA-identical sibling | 1968 (37) |
| Other related | 226 (4) |
| Well-matched unrelated | 1261 (24) |
| Partially matched unrelated | 1060 (20) |
| Mismatched unrelated | 532 (10) |
| Missing HLA data | 296 (6) |
| Conditioning regimen | |
| Myeloablative | 4749 (89) |
| Reduced intensity/nonmyeloablative | 594 (11) |
| Donor-recipient gender match | |
| Male donor → male recipient | 1804 (34) |
| Male donor → female recipient | 1105 (21) |
| Female donor → male recipient | 1378 (26) |
| Female donor → female recipient | 1056 (20) |
| Donor-recipient CMV match | |
| Donor(−)/recipient(−) | 1561 (29) |
| Donor(−)/recipient(+) | 1140 (21) |
| Donor(+)/recipient(−) | 697 (13) |
| Donor(+)/recipient(+) | 1688 (32) |
| Unknown | 257 (5) |
| GVHD prophylaxis | |
| T-cell depletion | 1242 (23) |
| CSA ± MTX ± other | 3341 (63) |
| FK506 ± MTX ± other | 760 (14) |
| Year of transplantation | |
| 1995-1999 | 2742 (51) |
| 2000-2004 | 2601 (49) |
| Grade of acute GHVD | |
| None | 1433 (27) |
| I-II | 2258 (42) |
| III-IV | 1652 (31) |
| Time from transplantation to cGHVD, mo (range) | 5 (1-11) |
| Onset of cGVHD | |
| Progressive | 2301 (43) |
| Quiescent | 1430 (27) |
| De novo | 1433 (27) |
| Missing | 179 (3) |
| Maximum grade of cGVHD | |
| Limited | 1707 (32) |
| Extensive | 3636 (68) |
| Karnofsky score at diagnosis of cGVHD | |
| < 80 | 1570 (29) |
| 80-100 | 3007 (56) |
| Unknown | 766 (14) |
| Platelet count at cGVHD, × 109/L | |
| Median (range) | 117 (< 1-718) |
| < 100 | 1921 (36) |
| ≥ 100 | 2650 (50) |
| Missing | 772 (14) |
| Serum bilirubin at cGVHD, mg/dL | |
| Median (range) | 1 (< 1-98) |
| < 1 | 2928 (55) |
| 1-2 | 982 (18) |
| > 2 | 925 (17) |
| Missing | 508 (10) |
| Duration of immunosuppression | |
| < 1 y | 1953 (37) |
| 1-2 y | 650 (12) |
| 2-3 y | 404 (8) |
| 3-4 y | 371 (7) |
| > 4 y | 1007 (19) |
| Missing | 958 (18) |
| Median follow-up of survivors, mo | 73 (3-168) |
| Characteristics . | n (%) . |
|---|---|
| Number of patients | 5343 |
| Number of centers | 286 |
| Age at transplantation, y | |
| Median (range) | 36 (< 1-72) |
| 0-9 | 451 (8) |
| 10-19 | 665 (12) |
| 20-29 | 906 (17) |
| 30-39 | 1207 (23) |
| 40-49 | 1212 (23) |
| 50-59 | 742 (14) |
| ≥ 60 | 160 (3) |
| Male sex | 3182 (60) |
| Disease | |
| AML | 1802 (34) |
| ALL | 1140 (21) |
| CML | 1813 (34) |
| MDS | 588 (11) |
| Disease status before transplantation* | |
| Early | 2956 (55) |
| Intermediate | 1367 (26) |
| Advanced | 1020 (19) |
| Graft source | |
| Bone marrow | 3302 (62) |
| Peripheral blood | 1914 (36) |
| Umbilical cord blood | 127 (2) |
| HLA-matching status† | |
| HLA-identical sibling | 1968 (37) |
| Other related | 226 (4) |
| Well-matched unrelated | 1261 (24) |
| Partially matched unrelated | 1060 (20) |
| Mismatched unrelated | 532 (10) |
| Missing HLA data | 296 (6) |
| Conditioning regimen | |
| Myeloablative | 4749 (89) |
| Reduced intensity/nonmyeloablative | 594 (11) |
| Donor-recipient gender match | |
| Male donor → male recipient | 1804 (34) |
| Male donor → female recipient | 1105 (21) |
| Female donor → male recipient | 1378 (26) |
| Female donor → female recipient | 1056 (20) |
| Donor-recipient CMV match | |
| Donor(−)/recipient(−) | 1561 (29) |
| Donor(−)/recipient(+) | 1140 (21) |
| Donor(+)/recipient(−) | 697 (13) |
| Donor(+)/recipient(+) | 1688 (32) |
| Unknown | 257 (5) |
| GVHD prophylaxis | |
| T-cell depletion | 1242 (23) |
| CSA ± MTX ± other | 3341 (63) |
| FK506 ± MTX ± other | 760 (14) |
| Year of transplantation | |
| 1995-1999 | 2742 (51) |
| 2000-2004 | 2601 (49) |
| Grade of acute GHVD | |
| None | 1433 (27) |
| I-II | 2258 (42) |
| III-IV | 1652 (31) |
| Time from transplantation to cGHVD, mo (range) | 5 (1-11) |
| Onset of cGVHD | |
| Progressive | 2301 (43) |
| Quiescent | 1430 (27) |
| De novo | 1433 (27) |
| Missing | 179 (3) |
| Maximum grade of cGVHD | |
| Limited | 1707 (32) |
| Extensive | 3636 (68) |
| Karnofsky score at diagnosis of cGVHD | |
| < 80 | 1570 (29) |
| 80-100 | 3007 (56) |
| Unknown | 766 (14) |
| Platelet count at cGVHD, × 109/L | |
| Median (range) | 117 (< 1-718) |
| < 100 | 1921 (36) |
| ≥ 100 | 2650 (50) |
| Missing | 772 (14) |
| Serum bilirubin at cGVHD, mg/dL | |
| Median (range) | 1 (< 1-98) |
| < 1 | 2928 (55) |
| 1-2 | 982 (18) |
| > 2 | 925 (17) |
| Missing | 508 (10) |
| Duration of immunosuppression | |
| < 1 y | 1953 (37) |
| 1-2 y | 650 (12) |
| 2-3 y | 404 (8) |
| 3-4 y | 371 (7) |
| > 4 y | 1007 (19) |
| Missing | 958 (18) |
| Median follow-up of survivors, mo | 73 (3-168) |
AML indicates acute myeloid leukemia; ALL, acute lymphoid leukemia; CML, chronic myeloid leukemia; CMV, cytomegalovirus; MDS, myelodysplastic syndrome; CSA, cyclosporine, and MTX, methotrexate, FK506:tacrolimus.
Disease status before transplantation was defined as follows: early disease included patients undergoing HCT in first remission (acute leukemia) or first chronic phase (CML) or MDS with refractory anemia or refractory anemia with ringed sideroblasts (RA, RARS); intermediate disease was defined as second or later complete remission (ALL), second or later chronic phase/accelerated phase (CML); and advanced disease included patients in relapse or primary induction failure (acute leukemia) or blast crisis (CML) or MDS with refractory anemia with excess blasts or excess blasts in transformation
HLA-matching criteria used were as defined by Weisdorf et al.20 : well-matched, no defined mismatches and no untested HLA locus; partially matched, only one untested or mismatched locus; and mismatched, 2 or more known or mismatched or untested HLA loci.